HK1060062A1 - Antineoplastic combinations comprising cci-779 ( rapamycin derivative) together with gemcitabine or fluorouracil - Google Patents

Antineoplastic combinations comprising cci-779 ( rapamycin derivative) together with gemcitabine or fluorouracil

Info

Publication number
HK1060062A1
HK1060062A1 HK04103071A HK04103071A HK1060062A1 HK 1060062 A1 HK1060062 A1 HK 1060062A1 HK 04103071 A HK04103071 A HK 04103071A HK 04103071 A HK04103071 A HK 04103071A HK 1060062 A1 HK1060062 A1 HK 1060062A1
Authority
HK
Hong Kong
Prior art keywords
fluorouracil
cci
gemcitabine
rapamycin derivative
antineoplastic combinations
Prior art date
Application number
HK04103071A
Other languages
English (en)
Inventor
James Joseph Gibbons Jr
Gary Dukart
Jurgen Hermann Ernst Frish
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of HK1060062A1 publication Critical patent/HK1060062A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK04103071A 2001-04-06 2004-04-30 Antineoplastic combinations comprising cci-779 ( rapamycin derivative) together with gemcitabine or fluorouracil HK1060062A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28238501P 2001-04-06 2001-04-06
US28238801P 2001-04-06 2001-04-06
PCT/US2002/010912 WO2002080975A1 (en) 2001-04-06 2002-04-05 Antineoplastic combinations such as rapamycin together with gemcitabine or fluorouracil

Publications (1)

Publication Number Publication Date
HK1060062A1 true HK1060062A1 (en) 2004-07-30

Family

ID=26961412

Family Applications (1)

Application Number Title Priority Date Filing Date
HK04103071A HK1060062A1 (en) 2001-04-06 2004-04-30 Antineoplastic combinations comprising cci-779 ( rapamycin derivative) together with gemcitabine or fluorouracil

Country Status (22)

Country Link
EP (1) EP1385551B1 (pl)
JP (1) JP2004525950A (pl)
KR (1) KR100862178B1 (pl)
CN (1) CN1309421C (pl)
AT (1) ATE406892T1 (pl)
AU (1) AU2007242958A1 (pl)
BR (1) BR0208627A (pl)
CA (1) CA2442849A1 (pl)
DE (1) DE60228699D1 (pl)
EA (1) EA010184B1 (pl)
ES (1) ES2312568T3 (pl)
HK (1) HK1060062A1 (pl)
HU (1) HUP0304093A3 (pl)
IL (1) IL157898A0 (pl)
MX (1) MXPA03009092A (pl)
NO (1) NO20034433L (pl)
NZ (1) NZ540047A (pl)
PL (1) PL363991A1 (pl)
PT (1) PT1385551E (pl)
SG (1) SG152906A1 (pl)
SI (1) SI1385551T1 (pl)
WO (1) WO2002080975A1 (pl)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001295986B2 (en) 2000-10-20 2006-08-17 Eisai R&D Management Co., Ltd Nitrogenous aromatic ring compounds
DK3143995T3 (en) 2001-02-19 2019-01-28 Novartis Pharma Ag Rapamycin derivative for the treatment of lung cancer
GB0124577D0 (en) * 2001-10-12 2001-12-05 Novartis Forschungsstiftung Novel methods
JP4547911B2 (ja) 2002-02-01 2010-09-22 アリアド・ファーマシューティカルズ・インコーポレイテッド リン含有化合物およびその用途
UA83484C2 (uk) * 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
CN101337930B (zh) 2003-11-11 2010-09-08 卫材R&D管理有限公司 脲衍生物的制备方法
AU2005216898A1 (en) * 2004-02-26 2005-09-09 The Penn State Research Foundation Combinatorial therapies for the treatment of neoplasias using the opioid growth factor receptor
WO2006027545A2 (en) * 2004-09-10 2006-03-16 Agency For Science, Technology And Research Method
JP4834553B2 (ja) 2004-09-17 2011-12-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 医薬組成物
CN102886045A (zh) 2005-02-03 2013-01-23 综合医院公司 治疗吉非替尼耐药性癌症的方法
JP4989476B2 (ja) 2005-08-02 2012-08-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質の効果を検定する方法
EP3488866A1 (en) * 2005-11-04 2019-05-29 Wyeth LLC Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
CA2629714A1 (en) * 2005-11-14 2007-05-24 Ariad Gene Therapeutics, Inc. Administration of an mtor inhibitor to treat patients with cancer
GB0523658D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
DK2275103T3 (da) * 2005-11-21 2014-07-07 Novartis Ag mTor-inhibitorer ved behandling af endokrine tumorer
WO2007080124A1 (en) * 2006-01-12 2007-07-19 Novartis Ag Combination of mtor inhibitor and antipolate compound
EP1880723A1 (en) * 2006-07-14 2008-01-23 Novartis AG Combination of mTOR inhibitor and antifolate compound
EP1996193A2 (en) 2006-03-13 2008-12-03 OSI Pharmaceuticals, Inc. Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors
EP2004163B1 (en) * 2006-04-05 2014-09-17 Novartis Pharma AG Combination of everolimus and vinorelbine
CA2652442C (en) 2006-05-18 2014-12-09 Eisai R & D Management Co., Ltd. Antitumor agent for thyroid cancer
JP2009539769A (ja) * 2006-06-02 2009-11-19 アリアド ジーン セラピューティクス インコーポレイテッド カペシタビン併用療法
EP2054061A4 (en) * 2006-08-02 2009-09-02 Ariad Pharma Inc COMBINATION THERAPY
CN101511793B (zh) 2006-08-28 2011-08-03 卫材R&D管理有限公司 针对未分化型胃癌的抗肿瘤剂
CA2683109A1 (en) * 2006-10-11 2008-04-17 Fusion Antibodies Limited Combination therapy
AU2007319825B2 (en) 2006-11-14 2014-01-23 Ariad Pharmaceuticals, Inc. Oral formulations
WO2008088088A1 (ja) 2007-01-19 2008-07-24 Eisai R & D Management Co., Ltd. 膵癌治療用組成物
CA2676796C (en) 2007-01-29 2016-02-23 Eisai R & D Management Co., Ltd. Composition for treatment of undifferentiated gastric cancer
PT2131821T (pt) * 2007-03-07 2018-10-10 Abraxis Bioscience Llc Nanopartícula que compreende rapamicina e albumina como agente anticancerígeno
US8927019B2 (en) 2007-06-01 2015-01-06 Abraxis Bioscience, Llc Methods and compositions for treating recurrent cancer
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
KR101513326B1 (ko) 2007-11-09 2015-04-17 에자이 알앤드디 매니지먼트 가부시키가이샤 혈관 신생 저해 물질과 항종양성 백금 착물의 병용
AU2009225434B2 (en) 2008-03-21 2014-05-22 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
US20090312360A1 (en) 2008-06-17 2009-12-17 Wyeth Antineoplastic Combinations Containing HKI-272 and Vinorelbine
JP5681108B2 (ja) 2008-08-04 2015-03-04 ワイス・エルエルシー ４−アニリノ−３−シアノキノリンとカペシタビンの抗新生物薬の組合せ
CA2755789C (en) 2009-04-06 2016-01-19 Wyeth Llc Treatment regimen utilizing neratinib for breast cancer
CN102958523B (zh) 2010-06-25 2014-11-19 卫材R&D管理有限公司 使用具有激酶抑制作用的组合的抗肿瘤剂
CN103402519B (zh) 2011-04-18 2015-11-25 卫材R&D管理有限公司 肿瘤治疗剂
EP2714937B1 (en) 2011-06-03 2018-11-14 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
KR20150098605A (ko) 2012-12-21 2015-08-28 에자이 알앤드디 매니지먼트 가부시키가이샤 퀴놀린 유도체의 비정질 형태 및 그의 제조방법
SG11201509278XA (en) 2013-05-14 2015-12-30 Eisai R&D Man Co Ltd Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
IL302218B1 (en) 2014-08-28 2024-06-01 Eisai R&D Man Co Ltd Methods for the production of lanvotinib and its derivatives in a high degree of purity
DK3263106T3 (da) 2015-02-25 2024-01-08 Eisai R&D Man Co Ltd Fremgangsmåde til undertrykkelse af bitterhed af quinolinderivat
AU2015384801B2 (en) 2015-03-04 2022-01-06 Eisai R&D Management Co., Ltd. Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
EP3311841B1 (en) 2015-06-16 2021-07-28 PRISM BioLab Co., Ltd. Anticancer agent
LT3436461T (lt) 2016-03-28 2024-03-12 Incyte Corporation Pirolotriazino junginiai kaip tam inhibitoriai
KR20210049088A (ko) 2018-06-29 2021-05-04 인사이트 코포레이션 Axl/mer 억제제의 제형

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5066493A (en) * 1978-11-03 1991-11-19 American Home Products Corporation Rapamycin in treatment of tumors
BE877700A (fr) * 1978-11-03 1980-01-14 Ayerst Mckenna & Harrison Compositions pharmaceutiques a base de rapamycine pour le traitement de tumeurs carcinogenes
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
DK0986570T3 (da) * 1997-01-24 2003-07-28 Conpharma As Gemcitabinderivat
TW466112B (en) * 1998-04-14 2001-12-01 Lilly Co Eli Novel use of 2'-deoxy-2',2'-difluorocytidine for immunosuppressive therapy and pharmaceutical composition comprising the same

Also Published As

Publication number Publication date
PT1385551E (pt) 2008-11-03
AU2007242958A1 (en) 2008-01-10
SG152906A1 (en) 2009-06-29
CN1545419A (zh) 2004-11-10
NO20034433L (no) 2003-11-25
EA010184B1 (ru) 2008-06-30
HUP0304093A2 (hu) 2004-04-28
MXPA03009092A (es) 2004-02-12
EA200301091A1 (ru) 2004-02-26
CA2442849A1 (en) 2002-10-17
HUP0304093A3 (en) 2008-08-28
KR20040007491A (ko) 2004-01-24
NZ540047A (en) 2007-01-26
BR0208627A (pt) 2004-03-09
PL363991A1 (pl) 2004-11-29
CN1309421C (zh) 2007-04-11
EP1385551B1 (en) 2008-09-03
IL157898A0 (en) 2004-03-28
ATE406892T1 (de) 2008-09-15
JP2004525950A (ja) 2004-08-26
ES2312568T3 (es) 2009-03-01
WO2002080975A1 (en) 2002-10-17
DE60228699D1 (de) 2008-10-16
NO20034433D0 (no) 2003-10-03
SI1385551T1 (sl) 2008-12-31
KR100862178B1 (ko) 2008-10-09
EP1385551A1 (en) 2004-02-04

Similar Documents

Publication Publication Date Title
HK1060062A1 (en) Antineoplastic combinations comprising cci-779 ( rapamycin derivative) together with gemcitabine or fluorouracil
SG148031A1 (en) Use of cci-779 as an antineoplastic agent
SG170612A1 (en) Antineoplastic combinations
MXPA05009246A (es) Combinaciones antineoplasicas.
CY2007019I2 (el) Β-αμινο-τετραϋδροϊμιδαζο-(1,2-α)-πυραζινες και τετραϋδροτριαζολο-(4,3-α)-πυραζινες ως αναστολεις της διπεπτιδυλο πεπτιδασης για την αγωγη ή προληψη του διαβητη
TW200420573A (en) Bifunctional heterocyclic compounds and methods of making and using same
DE60226666D1 (de) Wälz- und Gleitlagerbauteil und Wälzlager
WO2005087265A8 (en) Antineoplastic combinations of cci-779 and rituximab
MXPA05010582A (es) Combinaciones antineoplasicas.
SG153647A1 (en) Antineoplastic combinations
AR034071A1 (es) Combinaciones antineoplasicas
AR033012A1 (es) Combinaciones antineoplasicas
IL160960A0 (en) Reduced toxicity cisplatin formulations and methods for using the same

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20120405